Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
PARIS, FRANCE - Novacyt (EPA:ALNOV) S.A. (EURONEXT GROWTH:ALNOV; AIM:NCYT), a global molecular diagnostics company, announced today that it will release its audited financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. The company, known for its extensive portfolio of integrated technologies and services in genomic medicine, will host an investor webinar on the same day to discuss the results.
The webinar, scheduled for 11.00 am British Summer Time, will feature Novacyt’s CEO, Lyn Rees, and CFO, Steve Gibson. It will include a presentation of the fiscal year 2024 results followed by a question-and-answer session. Investors interested in participating can sign up through the Investor Meet Company platform, where they can also submit questions in advance or during the live event. The presentation will be accessible to a French-speaking audience with automated French subtitling.
Novacyt, headquartered in France with offices in the UK, Singapore, the US, and Canada, operates across three business segments: Clinical, Instrumentation, and Research Use Only. The company provides diagnostic products and services in reproductive health, precision medicine, and infectious diseases, among other areas. Its instrumentation portfolio includes next-generation DNA sample preparation platforms and rapid PCR machines.
The company’s commercial presence spans over 65 countries, and it is listed on both the London Stock Exchange (LON:LSEG)’s AIM market and the Paris Stock Exchange Euronext (EPA:ENX) Growth.
The forthcoming financial results will offer investors insights into Novacyt’s performance and strategic direction in the previous year. This announcement is based on a press release statement from Novacyt S.A.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.